Table of Contents
Chromatography Research International
Volume 2011, Article ID 929876, 9 pages
http://dx.doi.org/10.4061/2011/929876
Research Article

Stability-Indicating Gradient RP-LC Method for the Determination of Process and Degradation Impurities in Bosentan Monohydrate: An Endothelin Receptor Antagonist

1Research and Development, Megafine Pharma (P) Ltd., Nashik 422 202, India
2Department of Chemistry, Deogiri College, Aurangabad 431004, India

Received 16 June 2011; Revised 29 July 2011; Accepted 2 August 2011

Academic Editor: Cristina Minguillón

Copyright © 2011 Sanjay A. Jadhav et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. J. Rubin, D. B. Badesch, R. J. Barst et al., “Bosentan therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 346, no. 12, pp. 896–903, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Launay, O. Sitbon, J. L. Pavec et al., “Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil,” Rheumatology, vol. 49, no. 3, pp. 490–500, 2010. View at Google Scholar
  3. J. L. Vachiéry and G. Simonneau, “Management of severe pulmonary arterial hypertension,” European Respiratory Review, vol. 19, no. 118, pp. 279–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Afshar and A. Boyd-King, “Pharmacotherapy of systemic sclerosis: focus on bosentan,” Clinical Medicine, vol. 1, pp. 253–262, 2009. View at Google Scholar
  5. J. M. Pearl, S. A. Wellmann, J. L. McNamara et al., “Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function,” Annals of Thoracic Surgery, vol. 68, no. 5, pp. 1714–1721, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. M. M. Hoeper, N. Taha, A. Bekjarova, R. Gatzke, and E. Spiekerkoetter, “Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids,” European Respiratory Journal, vol. 22, no. 2, pp. 330–334, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Hoeper, T. Kramm, H. Wilkens et al., “Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension,” Chest, vol. 128, no. 4, pp. 2363–2367, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. K. Votava-Smith, G. S. Perens, and J. C. Alejos, “Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional glenn shunt,” Pediatric Cardiology, vol. 28, no. 4, pp. 314–316, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, and T. Higenbottam, “Guidelines on diagnosis and treatment of pulmonary arterial hypertension—the task force on diagnosis and treatment of pulmonary arterial hypertension of the european society of cardiology task force members,” European Heart Journal, vol. 25, no. 24, pp. 2243–2278, 2004. View at Google Scholar
  10. D. Dell, B. Lausecker, G. Hopfgartner, P. L. M. Van Giersbergen, and J. Dingemanse, “Evolving bioanalytical methods for the cardiovascular drug bosentan,” Chromatographia, vol. 55, pp. S115–S119, 2002. View at Google Scholar · View at Scopus
  11. B. Lausecker, B. Hess, G. Fischer, M. Mueller, and G. Hopfgartner, “Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection,” Journal of Chromatography B, vol. 749, no. 1, pp. 67–83, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Weber, R. Gasser, and G. Hopfgartner, “Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects,” Drug Metabolism and Disposition, vol. 27, no. 7, pp. 810–815, 1999. View at Google Scholar · View at Scopus
  13. T. K. Reddy, M. Younus, Y. R. Reddy, G. A. Kumar, and S. Sravan, “RP-HPLC method devlopment and valdation of bosentan drug present in tablets,” International Journal of Pharmacy & Technology, vol. 2, no. 3, pp. 577–587, 2010. View at Google Scholar
  14. International federation of Pharmaceutical Manufactures and Associations (IFPMA), “Impurities in new drug substances,” in Proceedings of the International conference on Harmonization, (ICH '06), Methodology Q3A(R2), Geneva, Switzerland, 2006.
  15. International federation of Pharmaceutical Manufactures and Associations (IFPMA), “Good manufacturing practice guide for active pharmaceutical ingredients,” in Proceedings of the International conference on Harmonization, (ICH '05), Methodology Q7A, Geneva, Switzerland, 2005.
  16. The United States Pharmacopeia, Validation of Compendial Methods, section 1225, United States Pharmacopeia, 32 edition, 2009.
  17. International federation of Pharmaceutical Manufactures and Associations (IFPMA), “Validation of analytical procedure,” in Proceedings of the International conference on Harmonization, (ICH '96), Methodology Q2(R1), Geneva, Switzerland, 1996.
  18. J. Ruan, P. Tattersall, R. Lozano, and P. Shah, “The role of forced degradation studies in stability indicating HPLC method development,” The American Pharmaceutical Review, vol. 9, no. 1, pp. 46–53, 2006. View at Google Scholar · View at Scopus
  19. M. Bakshi and S. Singh, “Development of validated stability-indicating assay methods—critical review,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 6, pp. 1011–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. V. T. Mathad, N. C. Niphade, K. M. Jagtap, and C. T. Gaikwad, “A novel process for preparation of bosentan,” Indian Patent 2266/MUM, 2010. View at Google Scholar
  21. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000401/WC500041457.pdf.
  22. L. R. Snyder, J. J. Kirkland, and J. L. Glajch, Practical LC Method Development, 1997.
  23. R. LoBrutto, A. Jones, Y. V. Kazakevich, and H. M. McNair, “Effect of the eluent pH and acidic modifiers in high-performance liquid chromatography retention of basic analytes,” Journal of Chromatography A, vol. 913, no. 1-2, pp. 173–187, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. “Benefits of a phenyl column,” Technical Information number TI087E, http://www.imtaktusa.com/site_media/files/technical_information/TI087E.pdf.
  25. A Newsletter of Practical Chromatographic Advice, “Column selectivity—a powerful tool when developing reversed-phase HPLC separations,” 2000, http://www.chem.agilent.com/cag/cabu/columnselectivity.pdf. View at Google Scholar
  26. “Efficiently analyze your most challenging compound. Deliver high-quality results faster,” http://www.chromtech.com/Catalog/ProductLine/brochures/Zorbax_Guide.pdf.